Abstract
Twenty-four evaluable patients with advanced, persistent or recurrent squamous cell carcinoma of the cervix were treated with 750 mg/m2 of gallium nitrate (NCS # 15200) every three weeks. No patient had prior cytotoxic chemotherapy. Two patients had a partial response (8.3%), ten patients had stable disease (41.7%), and twelve (50%) had increasing disease. The 95% upper confidence bound for response is 24.0%. The major toxicities were nausea, vomiting and anemia. Gallium nitrate has minimal activity in patients with previously untreated squamous cell carcinoma of the cervix.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Helman LJ, Slavik M: Gallium nitrate, Clinical Brochure. Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, 1976
Vaidya SG, Chaudhri MA, Morrison R, Whait D: Localization of gallium-67 in malignant neoplasms. Lancet 2: 911–914, 1970
Waalkes TP, Sankers K, Smith RG, Adamson RH: DNA polymerases of Walker 256 carcinosarcoma. Cancer Res 34: 385–391, 1974
Krakoff IH, Newman RA, Goldberg RS: Clinical toxicologic and pharmacologic studies of gallium nitrate. Cancer 44: 1722–1729, 1979
Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J: Cis-dichlorodiammineplatinum (11) in the treatment of gynecologic malignancies: Phase II trials by the Gynecologic Oncology Group. Cancer Treat Rep 63: 1549–1555, 1979
Author information
Authors and Affiliations
Additional information
Address for offprints: GOG Administrative Office, Suite 1945, 1234 Market Street, Philadelphia, PA 19107, USA
The following are participating institutions: University of Alabama at Birmingham (CA 12484), The Oregon Health Sciences Center University*, University of California Medical Center at Los Angeles (CA 13630), University of North Carolina School of Medicine (CA 23073), Bowman Gray School of Medicine of Wake Forest University (CA 21946), The Albany Medical College of Union University (CA 27469), University of Pittsburgh School of Medicine*, Eastern Virginia Medical School (CA 40296), State University of New York at Stony Brook* and Pennsylvania Hospital*. * = Unfunded
Rights and permissions
About this article
Cite this article
Malfetano, J.H., Blessing, J.A., Homesley, H.D. et al. A phase II trial of gallium nitrate (NSC #15200) in advanced or recurrent squamous cell carcinoma of the cervix. Invest New Drugs 9, 109–111 (1991). https://doi.org/10.1007/BF00194560
Issue Date:
DOI: https://doi.org/10.1007/BF00194560